Compare GSL & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSL | TRVI |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | Greece | United States |
| Employees | 7 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | N/A | 2019 |
| Metric | GSL | TRVI |
|---|---|---|
| Price | $41.00 | $14.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $44.00 | $21.55 |
| AVG Volume (30 Days) | 254.7K | ★ 1.8M |
| Earning Date | 05-18-2026 | 05-05-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.95 | $5.38 |
| 52 Week High | $42.70 | $16.12 |
| Indicator | GSL | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 55.18 | 51.15 |
| Support Level | $36.97 | $10.07 |
| Resistance Level | $41.40 | $16.12 |
| Average True Range (ATR) | 0.97 | 0.80 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 53.33 | 40.11 |
Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.